Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial which explored patient preference between darolutamide and enzalutamide in men with metastatic castration-resistant prostate cancer.
The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug,…
Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.
“Within this paper, we discussed the importance of conservative management and lifestyle modifications as initial steps in managing BPH,” says Eiftu S. Haile, MD.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with…
Both the SOLAR-STAGE and SOLAR-RECUR trials are currently enrolling patients with prostate cancer in the US, with additional sites expected to open in Europe later…
In this final iteration of a 3-part series, Shawn H. Marhamati, MD, MS, shares initial insights into benefits of Aquablation in an ASC environment.
Karine Tawagi, MD, highlights several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in…
“To answer this question, one must know what is and is not included in the global payment for the UDS, and the definition and instructions…
